Table 5.

Prevalence of aPL, LA, aCL, and anti-β2GpI in SSc, stratified by continent.

	aPL (%[95%CI]) N = 23	LA (%[95%CI]) N = 6	aCL (%[95%CI]) N = 21	anti-β2GpI (%[95%CI]) N = 9
Africa	25 [0–86]	5 [0–15]	9 [0–27]	50 [35–65]
	N = 2	N = 1	N = 2	N = 1
Asia	14 [9–21]	3 [0–8]	14 [6-24]	10 [4–18]
	N = 4	N = 1	N = 3	N = 1
Oceania	17 [5–34]	0 [0–0]	10 [8–12]	6 [5–8]
	N = 2	N = 1	N = 2	N = 1
Europe	15 [7–26]	1 [0–3]	9 [4–16]	5 [1–11]
	N = 11	N = 3	N = 10	N = 6
North America	6 [2–13]	NA	6 [2–13]	NA
	N = 3		N = 3
South America	9 [3–19]	NA	9 [3–19]	NA
	N = 1		N = 1

N, number of studies with available data; NA, not available.